Erythropoietin-induced optimization of renal function after warm Ischemia

Journal of Endourology

Volumn 23, Issue 3, 2009, Pages 359-365

  Phillips, Courtney K ^a   Hruby, Gregory W ^a   Mirabile, Gabriella ^a   Motamedinia, Piruz ^a   Lehman, Daniel S ^a   Okhunov, Zhamshid ^a   Singh, Harmanmeet ^a   Schwartz, Marissa ^a   Benson, Mitchell C ^a   Landman, Jaime ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ERYTHROPOIETIN; MANNITOL; SODIUM CHLORIDE; RECOMBINANT ERYTHROPOIETIN;

AERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CLAMP; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DOG; HEMATOCRIT; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KRUSKAL WALLIS TEST; LAPAROSCOPIC SURGERY; MICROALBUMINURIA; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RENAL ARTERY; RENAL PROTECTION; URINE; ALBUMINURIA; ANIMAL; BLOOD; DOSE RESPONSE; HUMAN; ISCHEMIA; KIDNEY; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; TIME;

ALBUMINURIA; ANIMALS; CREATININE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; TIME FACTORS; WARM ISCHEMIA;

EID: 65549122925     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2008.0183     Document Type: Article

References (33)

1. Grundmann R, Eichmann J, Keckstein J, Meusel E, Pichlmaier H. Relationship between the prolongation of warm ischemia and the maximum available preservation period. Surgery 1977;81:542-550.
2. Collins GM, Green RD, Boyer D, Jalasz NA. Protection of kidneys from warm ischemic injury. Dosage and timing of mannitol administration. Transplantation 1980;29:83-84.
3. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
4. Malhotra S, Savitz SI, Ocava L, Rosenbaum DM. Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J Neurosci Res 2006;83:19-27.
5. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994;266:F360-F366.
6. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79-85.
7. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003;17:1754-1755.
8. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48:176-184.
9. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005;19:33-40.
10. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
11. Semenza GL. HIF-1: Mediator of physiological and patho-physiological responses to hypoxia. J Appl Physiol 2000;88: 1474-1480.
12. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002;13:1721-1732.
13. Eickelberg O, Seebach F, Riordan M, et al. Functional activation of heat shock factor and hypoxia-inducible factor in the kidney. J Am Soc Nephrol 2002;13:2094-2101.
14. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
15. Ivan M, Kondo K, Yang H, et al. HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001;292:464-468.
16. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529-32537.
17. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-3015.
18. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:17771-17778.
19. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149-162.
20. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999;59: 3915-3918.
21. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 2005;42:233-241.
22. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-5564.
23. Prass K, Scharff A, Ruscher K, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003;34:1981-1986.
24. Baldwin DD, Maynes LJ, Berger KA, et al. Laparoscopic warm renal ischemia in the solitary porcine kidney model. Urology 2004;64:592-597.
25. Laven BA, Orvieto MA, Chuang MS, et al. Renal tolerance to prolonged warm ischemia time in a laparoscopic versus open surgery porcine model. J Urol 2004;172:2471-2474.
26. Orvieto MA, Tolhurst SR, Chuang MS, Lyon MB, Ritch CR, Rapp DE, Shalhav AL. Defining maximal renal tolerance to warm ischemia in porcine laparoscopic and open surgery model. Urology 2005;66:1111-1115.
27. Lee JI, Kim MJ, Park CS, Kim MC. Influence of ascorbic acid on BUN, creatinine, resistive index in canine renal ischemia-reperfusion injury. J Vet Sci 2006;7:79-81.
28. Montanes I, Badia A, Rengel MA, Lopez-Novoa JM. Renal cortical intermediary metabolism in the recovery phase of postischemic acute renal failure in the dog. Proc Soc Exp Biol Med 1992;199:321-326.
29. Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol 2003;16:63-74.
30. Kawata M, Takamoto S, Kitahori K, et al. Erythropoietin protects the central nervous system during prolonged hy-pothermic circulatory arrest: An experimental study in a canine model. J Thorac Cardiovasc Surg 2006;131:1331-1337.
31. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
32. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005;24:4442-4449.
33. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.